BLA 761336 · Altor Bioscience, LLC, An Indirect Wholly-Owned Su
Anktiva
Nogapendekin Alfa Inbakicept-Pmln · Intravesical
NovelCDER novel approval, Apr 22, 2024: To treat bladder cancer
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Apr 22, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
16
3 Phase 3, 5 recruiting
FAERS reports
49
23 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 27, 2026.
ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). ( 1 )
Mechanism: Nogapendekin alfa inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans -presented by the IL-15 receptor α to the shared IL-2/IL-15 receptor (βc and γc) on the surface of CD4 + and CD8 + T cells and NK cells. Binding of nogapendekin alfa inbakicept-pmln to its receptor results in proliferation and activation of NK, CD8 + , and memory T cells without proliferation of immuno-suppressive Treg cells. In...
Therapeutic areas: Oncology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 14, 2026 Supplement 2 · Efficacy LetterLabel
- Apr 22, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- ANKTIVA · nogapendekin alfa inbakicept-pmln 400mcg/0.4 mL · SOLUTION, INTRAVESICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nogapendekin Alfa Inbakicept" as an intervention, any sponsor and status, largest first.
- Testing a Combination of Vaccines for Cancer Prevention in Lynch SyndromePivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05419011 · 186 participants (planned) · Start May 8, 2023 · Primary completion Jul 1, 2027
Drug: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5; Nogapendekin Alfa and 1 more · For: Colorectal Carcinoma; Colorectal Neoplasm; Lynch Syndrome
Sites: Phoenix, Arizona; Tucson, Arizona; San Francisco, California · 14 sites in all
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerPivotal-lookingTerminated
ImmunityBio, Inc.Industry
NCT03520686 · 102 participants · Start May 18, 2018 · Primary completion Oct 13, 2025
Drug: NAI + Pembrolizumab; NAI + Nivolumab + Ipilimumab and 12 more · For: Non Small Cell Lung Cancer
Sites: Anchorage, Alaska; Hot Springs, Arkansas; El Segundo, California · 31 sites in all
ImmunityBio, Inc.Industry
NCT07628062 · 70 participants (planned) · Start Jul 22, 2026 · Primary completion Dec 31, 2030
Drug: Nogapendekin Alfa Inbakicept (NAI); hAd5-HPV Vaccine (IBRX-042) and 2 more · For: HPV-Positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Head and Neck Cancer
- NAI Plus Standard of Care Compared To SOC Alone Plus Standard of Care in Critically Ill Adults With SepsisNot yet recruiting
ImmunityBio, Inc.Industry
NCT07783789 · 50 participants (planned) · Start Jan 15, 2027 · Primary completion May 12, 2028
Drug: Nogapendekin alfa inbakicept (NAI); Placebo · For: Sepsis
ImmunityBio, Inc.Industry
NCT07123727 · 40 participants (planned) · Start Sep 4, 2025 · Primary completion Mar 2027
Drug: Anktiva · For: Long COVID; Long COVID Syndrome; Long Covid 19
Sites: El Segundo, California
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaActive, not recruiting
ImmunityBio, Inc.Industry
NCT06061809 · 34 participants (planned) · Start Aug 7, 2024 · Primary completion Dec 31, 2029
Drug: Bevacizumab; PD-L1 t-haNK and 1 more · For: Glioblastoma
Sites: El Segundo, California; Fullerton, California; Newport Beach, California · 4 sites in all
Washington University School of MedicineAcademic, hospital or other
NCT07355205 · 26 participants (planned) · Start Jul 7, 2026 · Primary completion Jul 31, 2032
Drug: Ipilimumab; Nivolumab and 1 more · For: Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent
Sites: St Louis, Missouri
ImmunityBio, Inc.Industry
NCT07108036 · 20 participants (planned) · Start Nov 14, 2025 · Primary completion Oct 2026
Drug: N-803 (IL-15 Superagonist) · For: Long COVID
Sites: San Francisco, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia10
- chills7
- pyrexia6
- dysuria5
- pollakiuria5
- anaemia4
- bladder pain4
- nausea4
- urinary tract infection4
- drug ineffective3
- haematuria3
- abdominal distension2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 26 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Anktiva (Nogapendekin Alfa Inbakic-PMln)
2024 spending
$2.9M
Beneficiaries
12
17 claims
Per beneficiary
$242,910
$89,966.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $2,914,926 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer.
Chang SS, Chamie K, Kramolowsky E, et al. · J Urol 2026 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).
Bansal A, Stoffel EM, Lim R, et al. · Front Immunol 2026 · Clinical Trial, Phase II, Randomized Controlled Trial
- Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-GuérinߜUnresponsive Nonmuscle-Invasive Bladder Cancer.
Chamie K, Chang SS, Kramolowsky EV, et al. · Urol Pract 2024 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Efficacy and safety of combination versus single-agent immunotherapy for BCG-unresponsive non-muscle-invasive bladder cancer.
Zhou Y, Yang X, Tian T, et al. · Front Immunol 2026 · Systematic Review
- Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances.
Alasker A, Alghafees M, Nammor T, et al. · BMC Urol 2026 · Systematic Review
- Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.
D'Andrea D, Mostafid H, Gontero P, et al. · Eur Urol Oncol 2025 · Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.